1-4 of 4
Ariel Berger
Close
Sort by
Journal Articles

Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis

Daanish Hoda, Edward Faber, Jr., Bradley Hunter, Abhinav Deol, Concetta Crivera, Carrie Riccobono, Ashraf Garrett, Carolyn C. Jackson, Jessica Fowler, Ariel Berger, Andrea L Lorden, Raj Stewart
Journal: Blood
Blood (2021) 138 (Supplement 1): 1932.
https://doi.org/10.1182/blood-2021-145943
Published: 2021
Journal Articles

Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies

Walter W Grubb, MS, Samuel Huse, BA, Naufil Alam, PhD, Samuel Dychter, MD, John R. Wingard, MD, Navneet S. Majhail, MD MS, Ariel Berger, MPH
Journal: Blood
Blood (2016) 128 (22): 1187.
https://doi.org/10.1182/blood.V128.22.1187.1187
Published: 2016
Journal Articles

Economic Burden of Infections Following Allogeneic Hematopoietic Cell Transplant for Hematologic Malignancies

Ariel Berger, MPH, Walter W Grubb, MS, Samuel Huse, Maitreyee Mohanty, MPharm PhD, John Ferraro, MBA, Moya Daniels, MS, Wendy J. Levin, MDMS
Journal: Blood
Blood (2015) 126 (23): 4500.
https://doi.org/10.1182/blood.V126.23.4500.4500
Published: 2015
Journal Articles

Cost-Effectiveness Of Lenalidomide and Bortezomib In Patients With Previously Untreated Multiple Myeloma (MM)

Gerry Oster, PhD, Ariel Berger, MPH, Rebecca Bornheimer, BA, Gary Binder, MBA, Yasir Nagarwala, MD
Journal: Blood
Blood (2013) 122 (21): 5604.
https://doi.org/10.1182/blood.V122.21.5604.5604
Published: 2013